ArticleTranslational pediatrics2026
Development and validation of a prediction model for 6-month early death in pediatric H3K27M-mutant diffuse intrinsic pontine glioma (DIPG).
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: H3K27M-mutant diffuse intrinsic pontine glioma (H3K27M-DIPG) is among pediatric brain tumors with the poorest prognosis. Early identification of high-risk patients may facilitate timely, individualized clinical management. This study aimed to identify independent predictors of early death (ED), defined as death within 6 months of diagnosis, in pediatric patients with H3K27M-DIPG and to develop and validate a clinical prediction model to estimate individualized ED risk in this population. Methods: We retrospectively collected clinical data from 147 pediatric patients in the Surveillance, Epidemiology, and End Results (SEER), including sex, race, tumor grade, surgical approach, radiotherapy, chemotherapy, tumor size, age, and time from diagnosis to treatment. Death within 6 months of diagnosis was used as the primary outcome. To minimize the risk of omitting critical confounders while preventing overfitting, variables with P<0.15 in the univariable analysis were selected for multivariable logistic regression to construct a streamlined nomogram. The discriminatory ability of the model was evaluated by the area under the curve (AUC). Internal validation was performed using 500 bootstrap resamples to calculate the optimism-corrected C-index and verify model stability. Results: Following the univariable screening, four variables (radiotherapy, chemotherapy, time to treatment, and tumor grade) were incorporated into the multivariable model. Multivariable logistic regression analysis showed that non-receipt of radiotherapy was the sole independent risk factor for ED [odds ratio (OR) =8.00, 95% confidence interval (CI): 2.26-28.30, P=0.001]. The developed nomogram demonstrated excellent discrimination, and the apparent C-index (AUC) was 0.732 (95% CI: 0.607-0.854). After internal validation with 500 bootstrap resamples, the optimism-corrected C-index remained stable at 0.702. Conclusions: This study successfully developed and internally validated a streamlined 4-variable prediction model to estimate the risk of 6-month ED in children with H3K27M-DIPG. Radiotherapy status emerged as the singular most critical factor associated with ED. This model may assist clinicians in early identification of high-risk patients, facilitate transparent clinician-family communication, and support individualized treatment planning and counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.